Ultragenyx Pharmaceutical Inc
RARE
41.42USD+0.31Â (+0.75%)Market ClosedWatchlist
Market Summary
USD41.42+0.31
Market Closed0.75%
RARE Stock Price
View Fullscreen
RARE RSI Chart
RARE Valuation
RARE Price/Sales (Trailing)
RARE Profitability
RARE Fundamentals
RARE Revenue
RARE Earnings
Price Action
Last 7 days
5.1%
Last 30 days
8.7%
Last 90 days
-0.1%
Trailing 12 Months
4.8%
How does RARE drawdown profile look like?
RARE Financial Health
RARE Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 383.9M | 402.9M | 410.2M | 0 |
| 2022 | 331.9M | 334.3M | 343.4M | 363.3M |
| 2021 | 334.1M | 359.4M | 359.6M | 351.4M |
| 2020 | 121.9M | 159.4M | 215.1M | 271.0M |
| 2019 | 59.0M | 70.3M | 84.4M | 103.7M |
| 2018 | 14.2M | 25.8M | 37.3M | 51.5M |
| 2017 | 752.8K | 1.4M | 2.0M | 2.6M |
| 2016 | 0 | 0 | 0 | 133.0K |
| 2015 | 0 | 0 | 0 | 0 |
| 2014 | 0 | 0 | 0 | 0 |
| 2013 | 0 | 0 | 0 | 0 |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for RARE
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Oct 23, 2023 | kassberg thomas richard | sold | -1,307,200 | 32.78 | -39,878 | cbo & evp |
| Oct 23, 2023 | kassberg thomas richard | acquired | 273,563 | 6.86 | 39,878 | cbo & evp |
| Oct 19, 2023 | kakkis emil d | sold | -1,604,030 | 33.52 | -47,853 | president & ceo |
| Oct 19, 2023 | kakkis emil d | acquired | 328,272 | 6.86 | 47,853 | president & ceo |
| Oct 09, 2023 | horn howard | acquired | - | - | 80,366 | chief financial officer |
| Sep 07, 2023 | huizenga theodore alan | acquired | 42,000 | 21.00 | 2,000 | svp, chief accounting officer |
| Sep 07, 2023 | huizenga theodore alan | sold | -88,249 | 40.7995 | -2,163 | svp, chief accounting officer |
| Sep 05, 2023 | harris erik | sold | -227,760 | 37.96 | -6,000 | evp & chief commercial officer |
| Sep 01, 2023 | huizenga theodore alan | sold | -36,032 | 37.1467 | -970 | svp, chief accounting officer |
| Jun 30, 2023 | sanders corazon (corsee) d. | sold | -27,354 | 46.76 | -585 | - |
Which funds bought or sold RARE recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Nov 24, 2023 | DEUTSCHE BANK AG\ | added | 6.76 | -7,164,380 | 33,786,600 | 0.02% |
| Nov 21, 2023 | COMERICA BANK | reduced | -58.24 | 22,039 | 38,039 | -% |
| Nov 21, 2023 | Walleye Capital LLC | added | 1,057 | 7,283,350 | 8,199,680 | 0.02% |
| Nov 21, 2023 | Walleye Trading LLC | added | 4,782 | 508,362 | 522,201 | -% |
| Nov 17, 2023 | JACOBS LEVY EQUITY MANAGEMENT, INC | added | 23.83 | -1,199,650 | 26,676,100 | 0.16% |
| Nov 15, 2023 | JANE STREET GROUP, LLC | reduced | -61.8 | -2,523,910 | 1,057,020 | -% |
| Nov 15, 2023 | CAPTRUST FINANCIAL ADVISORS | reduced | -6.17 | -314,939 | 830,930 | -% |
| Nov 15, 2023 | Tudor Investment Corp Et Al | sold off | -100 | -1,703,070 | - | -% |
| Nov 15, 2023 | Crestwood Advisors Group LLC | added | 235 | 2,194,540 | 3,574,200 | 0.09% |
| Nov 15, 2023 | PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | reduced | -9.97 | -430,000 | 982,000 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Ultragenyx Pharmaceutical Inc
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Sep 11, 2023 | vanguard group inc | 10.12% | 7,236,523 | SC 13G/A | |
| Feb 14, 2023 | price t rowe associates inc /md/ | 5.8% | 4,096,388 | SC 13G/A | |
| Feb 14, 2023 | rtw investments, lp | 5.7% | 3,966,915 | SC 13G | |
| Feb 09, 2023 | vanguard group inc | 9.09% | 6,374,230 | SC 13G/A | |
| Feb 06, 2023 | wellington management group llp | 7.42% | 5,202,684 | SC 13G | |
| Feb 03, 2023 | blackrock inc. | 6.2% | 4,336,492 | SC 13G | |
| Jan 10, 2023 | federated hermes, inc. | 4.41% | 3,094,500 | SC 13G/A | |
| Mar 09, 2022 | blackrock inc. | 4.9% | 3,411,414 | SC 13G/A | |
| Feb 14, 2022 | federated hermes, inc. | 5.85% | 3,986,870 | SC 13G/A | |
| Feb 14, 2022 | price t rowe associates inc /md/ | 16.9% | 11,525,089 | SC 13G/A |
Recent SEC filings of Ultragenyx Pharmaceutical Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Nov 03, 2023 | 10-Q | Quarterly Report | |
| Nov 02, 2023 | 8-K | Current Report | |
| Oct 24, 2023 | 4 | Insider Trading | |
| Oct 23, 2023 | 8-K | Current Report | |
| Oct 23, 2023 | 4 | Insider Trading | |
| Oct 23, 2023 | 144 | Notice of Insider Sale Intent | |
| Oct 20, 2023 | 424B5 | Prospectus Filed | |
| Oct 19, 2023 | FWP | Prospectus Filed | |
| Oct 19, 2023 | 144 | Notice of Insider Sale Intent | |
| Oct 17, 2023 | 424B5 | Prospectus Filed |
Peers (Alternatives to Ultragenyx Pharmaceutical Inc)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HILS | 31.4B | - | 4.92% | 426363.59% | -3.6K | 218.4K | - | -102.45% |
MRNA | 30.7B | 10.7B | 11.84% | -53.56% | -8.86 | 2.88 | -53.67% | -129.46% |
ALNY | 22.0B | 1.7B | 4.71% | -20.32% | -43.06 | 12.74 | 79.37% | 56.87% |
BMRN | 17.7B | 2.3B | 23.54% | -7.88% | 120.62 | 7.68 | 15.05% | 75.21% |
INCY | 12.4B | 3.6B | 1.56% | -32.86% | 29.22 | 3.44 | 8.35% | -51.49% |
| MID-CAP | ||||||||
APLS | 7.5B | 272.9M | 38.55% | 34.32% | -12.3 | 27.32 | 141.38% | 4.43% |
BBIO | 5.6B | - | 16.25% | 246.63% | -9.66 | 48.33 | 54.84% | -12.96% |
ACAD | 3.5B | 631.9M | -10.80% | 43.56% | -23.56 | 5.55 | 23.54% | 31.53% |
AXSM | 3.3B | 223.4M | 11.07% | -7.88% | -16.26 | 14.69 | - | -26.24% |
ARWR | 2.6B | 240.7M | -11.66% | -25.68% | -12.44 | 10.6 | -1.03% | -16.59% |
| SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 7.85% | -14.88% | 24.07 | 4.29 | 81.69% | -7.29% |
NVAX | 662.5M | 1.0B | -19.01% | -66.75% | -1.21 | 0.63 | -43.15% | 58.48% |
INO | 100.5M | 6.4M | -2.56% | -78.77% | -0.61 | 15.6 | -44.11% | 50.48% |
IBIO | 42.3M | - | 410.00% | -4.38% | -0.65 | - | - | -29.23% |
CRBP | 26.3M | - | 17.86% | 4717.52% | -0.55 | - | - | -13.74% |
Ultragenyx Pharmaceutical Inc News
Latest updates
Financials for Ultragenyx Pharmaceutical Inc
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | -9.5% | 98,052,000 | 108,309,000 | 100,496,000 | 103,348,000 | 90,703,000 | 89,343,000 | 79,935,000 | 83,389,000 | 81,647,000 | 86,975,000 | 99,395,000 | 91,542,000 | 81,470,000 | 61,709,000 | 36,309,000 | 35,593,000 | 25,800,000 | 24,149,000 | 18,172,000 | 16,261,000 | 11,763,000 |
| Cost Of Revenue | 10.8% | 10,987,000 | 9,914,000 | 12,257,000 | 5,319,000 | 8,631,000 | 8,270,000 | 6,100,000 | 3,509,000 | 4,175,000 | 3,136,000 | 5,188,000 | 5,481,000 | 2,348,000 | 1,803,000 | -3,503,000 | 5,107,000 | 2,683,000 | 766,000 | 452,000 | 507,000 | 273,000 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 169,751,000 | 205,964,000 | 187,623,000 | 131,785,000 | 124,764,000 | 156,974,000 | 130,045,000 | 143,833,000 | 136,623,000 | 117,386,000 | 106,601,000 | 101,409,000 |
| S&GA Expenses | -8.0% | 74,917,000 | 81,403,000 | 76,646,000 | 72,849,000 | 69,841,000 | 68,137,000 | 67,312,000 | 59,431,000 | 53,883,000 | 53,410,000 | 53,258,000 | 51,042,000 | 42,123,000 | 42,252,000 | 47,516,000 | 41,877,000 | 41,006,000 | 39,812,000 | 38,829,000 | 34,476,000 | 31,095,000 |
| R&D Expenses | -4.7% | 157,245,000 | 164,949,000 | 165,698,000 | 170,808,000 | 237,297,000 | 154,529,000 | 143,155,000 | 123,013,000 | 113,417,000 | 113,205,000 | 147,518,000 | 131,100,000 | 87,314,000 | 80,709,000 | 112,961,000 | 83,061,000 | 100,144,000 | 96,045,000 | 78,105,000 | 71,618,000 | 70,041,000 |
| EBITDA Margin | - | - | - | -1.81 | -1.88 | -1.90 | -1.46 | -1.37 | -1.25 | -0.95 | -0.94 | -0.57 | -0.64 | -1.12 | -1.80 | -3.38 | -3.77 | - | - | - | - | - |
| Income Taxes | -11.2% | 650,000 | 732,000 | 495,000 | -1,451,000 | 6,287,000 | 302,000 | 558,000 | 20,000 | 182,000 | 463,000 | 379,000 | 70,000 | 313,000 | 415,000 | 409,000 | 2,561,000 | 293,000 | 213,000 | 216,000 | 126,000 | 247,000 |
| Earnings Before Taxes | 0.1% | -158,999,000 | -159,096,000 | -163,477,000 | -153,284,000 | -238,819,000 | -157,860,000 | -151,762,000 | -122,438,000 | -72,816,000 | -121,965,000 | -135,762,000 | -23,941,000 | -68,532,000 | 25,730,000 | -118,616,000 | -91,244,000 | -112,701,000 | -98,959,000 | -96,540,000 | -87,700,000 | -87,063,000 |
| EBT Margin | - | - | - | -1.86 | -1.93 | -1.95 | -1.51 | -1.41 | -1.29 | -0.99 | -0.97 | -0.61 | -0.68 | -1.17 | -1.86 | -3.46 | -3.85 | - | - | - | - | - |
| Net Income | 0.1% | -159,649,000 | -159,828,000 | -163,972,000 | -151,833,000 | -245,106,000 | -158,162,000 | -152,320,000 | -122,458,000 | -72,998,000 | -122,428,000 | -136,141,000 | -24,011,000 | -68,845,000 | 25,315,000 | -119,025,000 | -93,805,000 | -112,994,000 | -99,172,000 | -96,756,000 | -87,826,000 | -87,310,000 |
| Net Income Margin | - | - | - | -1.87 | -1.95 | -1.97 | -1.51 | -1.42 | -1.29 | -0.99 | -0.98 | -0.61 | -0.69 | -1.19 | -1.89 | -3.49 | -3.88 | - | - | - | - | - |
| Free Cashflow | - | - | - | -181,901,000 | -117,312,000 | -121,391,000 | -108,180,000 | -149,705,000 | -70,392,000 | -80,209,000 | -85,427,000 | -175,760,000 | -84,398,000 | -65,747,000 | 83,268,000 | -109,248,000 | -83,539,000 | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | -5.6% | 1,238 | 1,311 | 1,383 | 1,545 | 1,618 | 1,321 | 1,384 | 1,522 | 1,485 | 1,512 | 1,598 | 1,760 | 1,268 | 1,314 | 1,233 | 1,135 | 880 | 959 | 1,008 | 720 | 765 |
| Current Assets | -14.7% | 599 | 702 | 766 | 884 | 1,013 | 679 | 708 | 857 | 847 | 949 | 1,071 | 1,295 | 872 | 906 | 894 | 851 | 613 | 699 | 787 | 522 | 567 |
| Cash Equivalents | -28.9% | 73.00 | 102 | 86.00 | 133 | 392 | 160 | 154 | 308 | 198 | 291 | 384 | 714 | 197 | 336 | 298 | 434 | 123 | 131 | 270 | 113 | 83.00 |
| Inventory | 12.5% | 32.00 | 28.00 | 27.00 | 27.00 | 22.00 | 21.00 | 18.00 | 16.00 | 15.00 | 15.00 | 12.00 | 13.00 | 14.00 | 11.00 | 11.00 | 12.00 | 14.00 | 14.00 | 11.00 | 7.00 | 6.00 |
| Net PPE | 2.7% | 297 | 289 | 278 | 260 | 235 | 207 | 177 | 141 | 119 | 105 | 88.00 | 74.00 | 49.00 | 48.00 | 48.00 | 44.00 | 32.00 | 25.00 | 22.00 | 20.00 | 20.00 |
| Goodwill | 0% | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 | 44.00 |
| Liabilities | 2.0% | 1,206 | 1,182 | 1,163 | 1,193 | 1,150 | 643 | 588 | 600 | 551 | 540 | 543 | 605 | 602 | 618 | 624 | 482 | 153 | 139 | 121 | 111 | 103 |
| Current Liabilities | 3.9% | 254 | 244 | 218 | 261 | 227 | 221 | 167 | 181 | 136 | 127 | 127 | 190 | 201 | 220 | 197 | 103 | 90.00 | 75.00 | 67.00 | 75.00 | 67.00 |
| Shareholder's Equity | -75.4% | 32.00 | 129 | 220 | 352 | 469 | 678 | 796 | 923 | 934 | 972 | 1,055 | 1,154 | 666 | 696 | 609 | 654 | 727 | 820 | 887 | 609 | 663 |
| Retained Earnings | -5.1% | -3,264 | -3,104 | -2,944 | -2,781 | -2,629 | -2,384 | -2,225 | -2,073 | -1,951 | -1,878 | -1,755 | -1,619 | -1,595 | -1,526 | -1,552 | -1,433 | -1,339 | -1,226 | -1,127 | -1,030 | -942 |
| Additional Paid-In Capital | 1.9% | 3,298 | 3,237 | 3,169 | 3,140 | 3,108 | 3,071 | 3,029 | 2,997 | 2,885 | 2,850 | 2,810 | 2,773 | 2,261 | 2,221 | 2,163 | 2,087 | 2,066 | 2,046 | 2,014 | 1,640 | 1,605 |
| Shares Outstanding | 1.0% | 72.00 | 71.00 | 71.00 | 70.00 | 70.00 | 70.00 | 70.00 | 69.00 | 68.00 | 68.00 | 67.00 | 67.00 | 60.00 | 60.00 | 58.00 | 57.00 | 58.00 | 58.00 | 53.00 | 50.00 | 50.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Quarterly) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | -1.5% | -117 | -116 | -156 | -90.34 | -95.34 | -77.26 | -117 | -54.34 | -59.65 | -65.36 | -159 | -62.45 | -61.97 | 87.00 | -95.15 | -72.04 | -88.51 | -89.06 | -95.77 | -55.85 | -69.16 |
| Share Based Compensation | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.00 | 20.00 | 22.00 | 20.00 | 21.00 | 21.00 |
| Cashflow From Investing | -35.3% | 64.00 | 99.00 | 111 | -171 | -161 | 79.00 | -37.36 | 69.00 | -40.76 | -41.25 | -182 | 98.00 | -95.76 | -86.14 | -95.12 | 67.00 | 79.00 | -58.43 | -101 | 74.00 | 16.00 |
| Cashflow From Financing | -23.6% | 25.00 | 33.00 | -0.72 | 2.00 | 492 | 6.00 | 2.00 | 86.00 | 8.00 | 13.00 | 13.00 | 490 | 19.00 | 36.00 | 56.00 | 315 | 1.00 | 9.00 | 354 | 12.00 | 25.00 |
RARE Income Statement
2023-09-30CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Revenues: | ||||
| Total revenues | $ 98,052 | $ 90,703 | $ 306,857 | $ 259,981 |
| Operating expenses: | ||||
| Cost of sales | 10,987 | 8,631 | 33,158 | 23,001 |
| Research and development | 157,245 | 237,297 | 487,892 | 534,981 |
| Selling, general and administrative | 74,917 | 69,841 | 232,966 | 205,290 |
| Total operating expenses | 243,149 | 315,769 | 754,016 | 763,272 |
| Loss from operations | (145,097) | (225,066) | (447,159) | (503,291) |
| Interest income | 5,881 | 3,483 | 18,135 | 4,876 |
| Change in fair value of equity investments | (1,419) | (1,626) | (1,492) | (21,139) |
| Non-cash interest expense on liabilities for sales of future royalties | (17,665) | (14,505) | (48,676) | (27,141) |
| Other expense | (699) | (1,105) | (2,380) | (1,746) |
| Loss before income taxes | (158,999) | (238,819) | (481,572) | (548,441) |
| Provision for income taxes | (650) | (6,287) | (1,877) | (7,147) |
| Net loss | $ (159,649) | $ (245,106) | $ (483,449) | $ (555,588) |
| Earnings per share, Basic | $ (2.23) | $ (3.5) | $ (6.81) | $ (7.96) |
| Earnings per share, Diluted | $ (2.23) | $ (3.5) | $ (6.81) | $ (7.96) |
| Weighted average number of shares outstanding, Basic | 71,664,493 | 70,054,173 | 70,987,801 | 69,834,037 |
| Weighted average number of shares outstanding, Diluted | 71,664,493 | 70,054,173 | 70,987,801 | 69,834,037 |
| Product sales | ||||
| Revenues: | ||||
| Total revenues | $ 42,349 | $ 32,503 | $ 128,757 | $ 90,019 |
| Royalty revenue | ||||
| Revenues: | ||||
| Total revenues | 55,703 | 5,373 | 106,916 | 15,634 |
| Collaboration and license | ||||
| Revenues: | ||||
| Total revenues | $ 0 | $ 52,827 | $ 71,184 | $ 154,328 |
RARE Balance Sheet
2023-09-30CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 72,575 | $ 132,944 |
| Marketable debt securities | 369,519 | 614,818 |
| Accounts receivable, net | 79,263 | 40,445 |
| Inventory | 31,802 | 26,766 |
| Prepaid expenses and other current assets | 46,029 | 68,926 |
| Total current assets | 599,188 | 883,899 |
| Property, plant, and equipment, net | 296,811 | 259,726 |
| Equity investments | 4,039 | 5,531 |
| Marketable debt securities | 82,071 | 148,970 |
| Right-of-use assets | 26,427 | 25,961 |
| Intangible assets, net | 157,302 | 160,105 |
| Goodwill | 44,406 | 44,406 |
| Other assets | 27,896 | 16,846 |
| Total assets | 1,238,140 | 1,545,444 |
| Current liabilities: | ||
| Accounts payable | 33,357 | 43,274 |
| Accrued liabilities | 178,622 | 204,678 |
| Contract liabilities | 0 | 1,479 |
| Lease liabilities | 12,067 | 11,779 |
| Liabilities for sales of future royalties | 29,932 | 0 |
| Total current liabilities | 253,978 | 261,210 |
| Lease liabilities | 34,555 | 19,814 |
| Deferred tax liabilities | 31,667 | 31,667 |
| Liabilities related to the sale of future royalties | 875,996 | 875,439 |
| Other liabilities | 10,230 | 4,820 |
| Total liabilities | 1,206,426 | 1,192,950 |
| Stockholders’ equity: | ||
| Preferred stock -25,000,000 shares authorized; nil outstanding as of outstanding as of September 30, 2023 and December 31, 2022 | 0 | 0 |
| Common stock - 250,000,000 shares authorized; 72,174,307 and 70,197,297 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | 72 | 70 |
| Treasury stock, at cost, 8,444 and nil shares held as of September 30, 2023 and December 31, 2022, respectively | (381) | 0 |
| Deferred compensation obligation | 381 | 0 |
| Additional paid-in capital | 3,298,357 | 3,140,019 |
| Accumulated other comprehensive loss | (2,244) | (6,573) |
| Accumulated deficit | (3,264,471) | (2,781,022) |
| Total stockholders’ equity | 31,714 | 352,494 |
| Total liabilities and stockholders’ equity | $ 1,238,140 | $ 1,545,444 |
| Â CEO | Dr. Emil D. Kakkis M.D., Ph.D. |
|---|---|
| Â WEBSITE | www.ultragenyx.com |
| Â EMPLOYEES | 1311 |